{"product_id":"cjc-1295-no-dac-5mg","title":"CJC-1295 NO DAC 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295nodacg.png?v=1779534335\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eCJC-1295 NO DAC is a research peptide designed for scientific investigation into growth hormone secretion and metabolic processes. This 5mg vial contains lyophilized peptide powder suitable for laboratory use and study protocols. CJC-1295 without DAC (Drug Affinity Complex) offers a shorter half-life compared to its DAC counterpart, making it ideal for researchers exploring acute dosing schedules and rapid pharmacokinetic profiles. The peptide works by stimulating growth hormone-releasing hormone (GHRH) pathways, providing a focused tool for investigating GH dynamics in controlled research settings. Each vial is manufactured to pharmaceutical-grade standards and supplied as a stable, freeze-dried powder. Reconstitution with bacteriostatic water is recommended for storage and handling. Suitable for qualified researchers and institutions conducting peptide research.\u003c\/p\u003e\n\u003cp\u003ePeptide Sequence: GHRH analog (modified) Molecular Weight: 2094.24 g\/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 5mg per vial Appearance: White to off-white lyophilized cake Storage: 2–8°C (refrigerated) or -20°C (long-term) Reconstitution: Bacteriostatic water (0.9% benzyl alcohol in saline) Half-life: 30 minutes (without DAC) Mechanism: GHRH receptor agonist Research Applications: GH secretion studies, metabolic research, pharmacokinetic investigations Stability: Stable when properly reconstituted and stored Intended Use: Research and laboratory use only Packaging: Sterile vial with flip-top cap\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C152H252N44O42\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution (Lyophilized Powder): Store in original vial at 2–8°C (refrigerated) for short-term use (up to 3 months). For long-term storage, keep at -20°C or below for up to 12 months. Protect from light and moisture. Keep vial sealed until ready for use. Avoid repeated freeze-thaw cycles. Storage After Reconstitution (Solution): Reconstituted solution should be stored at 2–8°C (refrigerated). Typical stability: 3–7 days when reconstituted with bacteriostatic water. Use sterile technique during reconstitution to maintain sterility. Store in sterile vials with appropriate sealing. Do not freeze reconstituted solution unless specifically required for your protocol. Discard any unused reconstituted solution after the recommended storage period.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Receptor Cloning and Agonist Binding\u003c\/strong\u003e\u003cbr\u003eMayo KE, et al. (1992). \u003cem\u003eMolecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.\u003c\/em\u003e Molecular Endocrinology, 6(10), 1734–1744. \u003ca href=\"https:\/\/doi.org\/10.1210\/mend.6.10.1333056\"\u003ehttps:\/\/doi.org\/10.1210\/mend.6.10.1333056\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which CJC-1295 (no DAC) exerts its GH-releasing effects and providing structural context for GHRH receptor agonist research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Pharmacokinetics: DAC vs. No-DAC Comparison\u003c\/strong\u003e\u003cbr\u003eJetté L, et al. (2005). \u003cem\u003ehGRF1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacokinetics and Pharmacodynamics of Eight Bioconjugates.\u003c\/em\u003e Journal of Pharmacology and Experimental Therapeutics, 317(3), 1228–1237. \u003ca href=\"https:\/\/doi.org\/10.1124\/jpet.105.089755\"\u003ehttps:\/\/doi.org\/10.1124\/jpet.105.089755\u003c\/a\u003e\u003cbr\u003eDirectly compares GHRH analogues with and without albumin-binding modifications, providing the key pharmacokinetic reference for the shorter half-life (~30 minutes) and pulsatile GH release pattern characteristic of the no-DAC form.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePulsatile GH Release and Physiological Relevance\u003c\/strong\u003e\u003cbr\u003eGiustina A \u0026amp; Veldhuis JD. (1998). \u003cem\u003ePathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.\u003c\/em\u003e Endocrine Reviews, 19(6), 717–797. \u003ca href=\"https:\/\/doi.org\/10.1210\/edrv.19.6.0353\"\u003ehttps:\/\/doi.org\/10.1210\/edrv.19.6.0353\u003c\/a\u003e\u003cbr\u003eComprehensive review of the neuroendocrine regulation of pulsatile GH secretion, providing essential physiological context for research using short-acting GHRH analogues such as CJC-1295 (no DAC) to model endogenous GH pulse dynamics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCJC-1295 Clinical Pharmacodynamics\u003c\/strong\u003e\u003cbr\u003eTeichman SL, et al. (2006). \u003cem\u003eProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.\u003c\/em\u003e Journal of Clinical Endocrinology \u0026amp; Metabolism, 91(3), 799–805. \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1536\"\u003ehttps:\/\/doi.org\/10.1210\/jc.2005-1536\u003c\/a\u003e\u003cbr\u003eProvides critical comparative pharmacodynamic data; the sustained GH\/IGF-1 elevation observed with the DAC form contrasts directly with the acute, pulsatile profile of CJC-1295 (no DAC), making this an essential reference for researchers designing short-acting GHRH protocol studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Analogues in Metabolic Research\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2007). \u003cem\u003eMetabolic effects of a growth hormone-releasing factor in patients with HIV.\u003c\/em\u003e New England Journal of Medicine, 357(23), 2359–2370. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa072375\"\u003ehttps:\/\/doi.org\/10.1056\/NEJMoa072375\u003c\/a\u003e\u003cbr\u003eInvestigates the metabolic effects of a GHRH(1–29) analogue in a clinical research setting, demonstrating changes in body composition and lipid metabolism — providing relevant context for researchers studying the downstream metabolic consequences of GHRH receptor activation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248700186967,"sku":"CND5","price":19.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/cjc-1295nodacg.png?v=1779534335","url":"https:\/\/www.mutantpeptides.com\/products\/cjc-1295-no-dac-5mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}